3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 1, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow PF06821497: new trials by email Literature Review of PF06821497 trials Research Report on PF06821497
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy Mevrometostat, Enzalutamide - Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma) | Phase 2 | Not yet recruiting | Prostate Cancer Clinical Trials Consortium | 60 | 2026-08-01 | 2026-05-18 |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Mevrometostat, Placebo, Enzalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | Pfizer | 1000 | 2025-09-28 | 2026-10-14 |
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. PF-06821497, Placebo, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Recruiting | Pfizer | 900 | 2024-10-22 | 2026-10-14 |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). PF-06821497, Docetaxel, Enzalutamide - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 3 | Active not recruiting | Pfizer | 600 | 2024-10-21 | 2026-08-11 |
| A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. Oral [14C] PF-06821497, Oral PF-06821497, IV [14C] PF-06821497 - Healthy Participants | Phase 1 | Completed | Pfizer | 6 | 2024-08-30 | 2025-01-23 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Mevrometostat (PF-06821497), Enzalutamide, Itraconazole - Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Pfizer | 453 | 2018-04-17 | 2026-10-15 |
Prostatic Neoplasms (3) · Recurrence (2) · Adenocarcinoma (1) · Lymphoma, Follicular (1) · Small Cell Lung Carcinoma (1)
Pfizer (6) · Prostate Cancer Clinical Trials Consortium (1)
China (4) · Japan (4) · Netherlands (4) · Poland (4) · South Korea (4) · Spain (4) · United States (4) · Argentina (3) · Brazil (3) · Bulgaria (3) · Canada (3) · Czechia (3) · France (3) · Germany (3) · Greece (3)
Atish Choudhury, MD, PhD (1) · Michael Schweizer, MD (1)
2023 (2)